Details

Autor(en) / Beteiligte

• Castañeda Amado, Zaira
• Toapanta, Néstor
• Jimenez, Sara
• Molina Gomez, Maria
• Maruri Kareaga, Naroa
• Llinás, Laura
• Villanego, Florentino
• Canal, Cristina
• Rodriguez, Marisa
• Montero, Nuria
• Vazquez-Sanchez, Teresa
• Gutierrez Dalmau, Alex
• Beneyto, Isabel
• Franco Esteve, Antonio
• María Vicente, Ana
• Lourdes Pérez Tamajón, M
• Leticia Martin-Moreno, Paloma
• Ramos, Ana
• Bestard, Oriol
• Moreso, Francesc

Titel

MO1017: Induction Immunosuppression and Outcome in Early Kidney Transplant Recipients with Covid-19

Ist Teil von

• Nephrology, dialysis, transplantation, 2022-05, Vol.37 (Supplement_3)

Erscheinungsjahr

2022

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract BACKGROUND AND AIMS COVID-19 in kidney transplants has a high risk of complications and mortality, especially in older recipients diagnosed during the early period after transplantation. Management of immunosuppression has been challenging during the pandemic. We investigated the impact of induction immunosuppression, either basiliximab or thymoglobulin, on the clinical evolution of kidney transplants developing COVID-19 during the early period after transplantation. METHOD Kidney transplant recipients with <6 months with a functioning graft diagnosed of COVID-19 from the initial pandemic outbreak (March 2020) until 31 July 2021 from different Spanish centres participating in a nationwide registry. RESULTS A total of 127 patients from 17 Spanish centres developed COVID-19 during the first 6 months after transplantation, 73 (57.5%) received basiliximab and 54 (42.5%) thymoglobulin. Demographics were not different between groups, but patients receiving thymoglobulin were more sensitized (cPRA of 32.7% ± 40.8% versus 5.6% ± 18.5%) and more frequently re-transplanted (30% versus 4%). Recipients older than 65 years treated with thymoglobulin showed the highest rate of acute respiratory distress syndrome [64.7% versus 37.1% for older recipients receiving thymoglobulin and basiliximab (P < .05), and 23.7% and 18.9% for young recipients receiving basiliximab and thymoglobulin (P > .05)] and the poorest survival [mortality rate of 64.7% and 42.9% for older recipients treated with thymoglobulin and basiliximab, respectively (P < .05), and 8.1% and 10.5% for young recipients treated with thymoglobulin and basiliximab (P > .05)]. Older recipients treated with thymoglobulin showed the poorest survival in the Cox's regression model adjusted for comorbidities. CONCLUSION Thymoglobulin should be used with caution in older recipients during the present pandemic era.